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in the XLPAD Registry
Karan Sarode1, Atif Mohammad1, Seth Jelinek2, Karthik D. Mekala2,
Avantika Banerjee3, Swagata Das3, Omar F. Hadidi4, Purav Mody5,
Donald Williams3, Andrew Klein6, Osvaldo Gigliotti2, Michael Luna4, Tayo Addo4,
Anand Prasad7, Emmanouil Brilakis1, Subhash Banerjee1
1VA North Texas Healthcare System and UT Southwestern Medical Center, Dallas,
TX, 2Seton Medical Center, Austin, TX, 3VA North Texas Healthcare System, Dallas,
TX, 4UT Southwestern Medical Center, Dallas, TX, 5University of Texas Southwestern
Medical Center, Dallas, TX, 6St. Louis VA Medical Center, St. Louis, United States,
7University of Texas Health Science Center at San Antonio, San Antonio, TX
Background: Successful crossing of superﬁcial femoral artery (SFA) and below the
knee (BTK) chronic total occlusions (CTO) often involves careful selection of a
primary crossing strategy. We compared CTO crossing success rates with a primary
wire-catheter or crossing device use.
Methods: We analyzed a total of 439 SFA and BTK CTO interventions in 316 pa-
tients enrolled in the multicenter Excellence in Peripheral Artery Disease (XLPAD)
registry (NCT01904851) between July 2005 and May 2014.
Results: A total of 295 (67.4%) procedures utilized a primary wire-catheter and 143
(32.6%) a primary crossing device. The crossing devices used were 52% Viance
(Covidien Inc., Dublin, Ireland), 32% Frontrunner (Cordis Corp., Bridgewater, NJ),
10% TruePath (Boston Scientiﬁc, Natick, MA), and 6% other. Both groups were
matched for lesion length (134.2 mm vs. 136.9 mm; p¼0.730) and location (82.8%
SFA vs. 79.7% SFA; p¼0.432). Primary crossing success was 51.9% in the ’wire-
catheter’ group; while 28.1% and 26.8% required provisional crossing or re-entry
devices, respectively. Primary success with a crossing device was 72.1% (Figure 1).
Provisional use of crossing device was higher in diabetics (55% vs. 42%; p¼0.044),
longer lesions (156.3  76.9 mm vs. 125.2  69.1 mm; p¼0.003), and in patients with
lower ankle-brachial indices (0.630.27 vs. 0.74  0.32; p¼0.011).Conclusions: Although most operators select a primary wire-catheter strategy to cross
infrainguinal CTO, primary crossing success is higher with crossing device use.
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Background:
Methods: The safety and efﬁcacy of the Misago superﬁcial femoral artery (SFA)
stent was evaluated prospectively in this initial collaboration trial between JapanJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Ilia(JP) and the United States (US) (Misago,Terumo corp., Tokyo, Japan). Since this
trial enrolled patients mainly from JP and US, and since there is question as to
whether race difference exists in SFA stent performance, the race-difference on
outcome was also analyzed. In addition, results were compared with a prior SFA
stent trial.
Results: The Misago stent was implanted in 261subjects with TASC A/B SFA
lesions (201 subjects in US, 50 in JP, 9 in Taiwan, 1 in South Korea). The mean
patient age was 69.3+/-10.0 and mean lesion length was 8.38+/-4.13 cm. The
overall 12 months primary patency rate and clinically driven TLR were 82.9% and
13.0%, respectively. When these results were compared with the Zilver PTX trial,
there were no difference in primary patency rate (OSPREY 82.9% vs Zilver PTX
89.9%; P¼0.206), non-TLR (87.0% vs 90.5%; P¼0.252) and stent fracture rate
(1.3% vs 0.9%; P¼0.694), however, stent thrombosis rate was statistically less
common in OSPREY (0.4% vs 2.7%; P< 0.05) (Zilver PTX, Cook Medical,
Bloomington,IN). As far as race difference within OSPREY trial, outcome between
US and non- US patients were similar including primary patency (82.9% versus
83.0%; P¼0.889), clinically driven TLR (13.4% versus 11.7%; P¼0.829), stent
fracture rate (1.5% versus 0.0%; P¼1.000) and stent thrombosis rate (0.5% versus
0.0%; P¼1.000).
Conclusions: OSPREY 12 months data showed satisfactory outcome of the Misago
stent for the treatment of TASC A/B SFA lesions and appears to be comparable to
drug eluting stent experience. In addition, the lack of difference in outcome among
race supports the value of international trials.
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Background: Femoropopliteal stenting for treatment of peripheral arterial disease has
shown superiority to balloon angioplasty (PTA) for the treatment of lifestyle limiting
claudication and critical limb ischemia. However, in-stent restenosis (ISR) after
femoropopliteal artery stenting remains a challenging therapeutic problem due pro-
cedural complications and repeat restenosis of up to 50%.
Methods: EXCITE ISR is a multi-center, prospective, randomized, controlled trial
comparing Excimer Laser Atherectomy (ELA; Spectranetics, Inc.) with adjunctive
PTA to PTA alone for the treatment of femoropopliteal ISR. A total of 335 patients
were planned for enrollment utilizing a 2:1 randomization structure (ELA +PTA:
PTA) at 40 centers in the United States. Primary inclusion criteria were Rutherford
class 1 to 4, total target treatment length  4 cm, vessel diameter 5-7 mm, and lesion
entirely crossable by an intraluminal guidewire. Primary endpoints were freedom from
major adverse event (MAE) through 30 days post-procedure and freedom from target
lesion revascularization (TLR) through 6 month follow up.
Results: Both groups were similar in baseline demographics and lesion characteris-
tics. Patients were predominantly male (63%) while nearly half were diabetic (47%)
and had a history of ISR (30%). Lesion length averaged 19 cm with 30% total oc-
clusion. The trial was stopped at 250 enrolled patients after successful primary
endpoint analysis. ELA + PTA demonstrated better procedural success with a sig-
niﬁcant reduction in procedural complications and post-treatment stenosis as
compared to PTA alone. The primary safety and efﬁcacy endpoints established su-
periority of ELA + PTA as compared to PTA alone.
Conclusions: The EXCITE ISR study is the ﬁrst trial conducted under an IDE to
support an FDA indication for femoropopliteal ISR. The complete 6 month results will
be provided to show that ELA + PTA is superior to PTA alone in the treatment of
femoropopliteal ISR.
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Background: Recent studies have reported higher 1-year primary patency and
lower rates of target lesion revascularization after endovascular treatment ofc and SFA B155
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vs. standard PTA. The overall impact of DCB use on medical care costs is
unknown.
Methods: We performed a prospective economic study alongside the IN.PACT SFA
II trial, which randomized patients with symptomatic fem-pop disease to DCB vs.
standard PTA and followed them for a minimum of 12 months. Detailed medical
resource utilization data were collected and costs were assigned for all US patients
using resource-based accounting (for revascularization procedures, medications and
outpatient vascular care) and hospital billing data for costs associated with the index
and follow-up hospitalizations for treatment of the target limb. The DCB was assigned
a cost of $1350/balloon.
Results: A total of 181 US patients were enrolled (121 DCB, 60 PTA). Initial hospital
costs were approximately $1100/patient higher in the DCB group than the PTA group
($8258 vs. $7164, p< 0.001), driven mainly by the cost of the DCB itself (see Table).
From discharge through 12 months, follow-up target-limb related medical care costs
werew$750/pt lower in the DCB group, such that total 1-year costs were similar for
the 2 groups ($10,034 vs. $9694, p¼0.82) with a resulting incremental cost-effec-
tiveness ratio of $2906 per repeat revascularization avoided - similar to that for cor-
onary drug-eluting stents.DCB
(n¼121)
Standard
PTA (n¼60) p-value
Index Procedure
and Hospitalization
Standard PTA balloons 1.3  0.5 2.3  0.7 <0.001
Drug-coated balloons 1.4  0.6 0.0  0.0 <0.001
Stents 0.1  0.3 0.2  0.5 0.067
Index procedure costs $5918  2425 $4604  2331 <0.001
Index hospitalization costs $8258  3223 $7164  3325 0.002
12-Month Follow-up
TVR events (per 100 pts) 11.6 76.6 23.3  62.1 0.005
Target limb
hospitalization-related costs
$1324  9148 $1975  5260 0.002
Medication costs $348  440 $344  277 0.378
Physician fees $104 574 $211  522 0.002
Total follow-up costs $1777  9699 $2530  5823 0.067
Total 1-year costs $10,034  10836 $9694  6884 0.459Conclusions: For patients with symptomatic fem-pop disease, use of the DCB was
associated with higher initial costs compared with standard PTA, but these were
largely offset by lower costs for follow-up target limb procedures through 1-year of
follow-up. The cost-effectiveness of DCB for such patients appears to compare
favorably with that for other cardiovascular interventions.
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Background: In-stent restenosis (ISR) after femoropopliteal artery stenting is a
signiﬁcant problem occurring in up to 50% of cases. The EXCITE ISR trial aimed
to demonstrate that procedural safety and efﬁcacy after debulking ISR lesions
with laser atherectomy is superior to balloon angioplasty (PTA) alone. Procedur-
ally, the Turbo Elite laser catheter (Spectranetics Inc., Colorado Springs, CO.) was
used to recanalize the ISR lesion prior to additional debulking with the Turbo
Tandem (Spectranetics Inc., Colorado Springs, CO) laser catheter. In this sub
analysis, outcomes were evaluated when optimal debulking is achieved with Turbo
Elite.
Methods: Angiographic residual stenosis post-Turbo Elite was available for 95 pa-
tients. Group 1 consisted of 25 patients in which atherectomy with Turbo Elite ach-
ieved 30% residual stenosis prior to any additional debulking with Turbo Tandem or
PTA treatment. Group 2 consisted of 70 patients in which 30% residual stenosis was
not achieved with Turbo Elite. Lesion characteristics and freedom from TLR through
6 months follow up is evaluated.
Results: Lesion length was similar: 19.5 cm vs 20.9 cm, Group 1 vs Group 2
respectively. Baseline diameter stenosis was similar (85% vs 89%; Group 1 vs Group
2), however there were more occlusions in Group 2 (28% vs 36%, p¼ns). Procedural
complications were similar for both groups as well as the average number of Turbo
Elite lasing trains. In amenable lesions (Group 1), there is little additional luminal
gain with Turbo Tandem or PTA after optimal debulking with Turbo Elite (table).
Furthermore, freedom from TLR is improved in Group 1. However, this is a statisticalB156 JACC Vol 64/1trend due to the low number of events until additional patients can be followed thru
6 months.Conclusions: Conclusions: This sub analysis of the EXCITE ISR trial demonstrates
that if optimal debulking is achieved with Turbo Elite, additional therapy is not
necessary.
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Background: Peripheral artery disease (PAD) has major worldwide health impact.
Stellarex (Covidien, Mansﬁeld, MA, USA) is an experimental paclitaxel-coated
PTA balloon designed for use in patients with PAD. The ILLUMENATE ﬁrst in
human (FIH) study was conducted at two German sites and enrolled patients with
superﬁcial femoral and/or popliteal artery lesions. Patients were followed for 24
months. This analysis was conducted to estimate the economic impact of the Stel-
larex drug-coated balloon (DCB) vs. uncoated PTA (PTA) at 12- and 24-month
follow-up.
Methods: Data from the ILLUMENATE FIH pre-dilatation cohort was compared
with a pooled and weighted PTA cohort from historical data. Costs for the baseline
procedure and clinically-driven target lesion revascularizations (TLRs) were
assigned to both groups using the 2013 German G-DRG reimbursement tariffs.
Budget impact models were constructed for 12- and 24-month follow up based on
total cost of the baseline procedure plus TLR (determined by TLR rates) in both
groups.
Results: The Stellarex (n¼50) and the pooled PTA cohorts (n¼139) were balanced
with respect to baseline characteristics. Between 12 and 24 months there were no
additional TLR events for the DCB treated patients while there were 17 additional
TLR’s in PTA patients. The budget impact model demonstrated cost advantages for
Stellarex through 24 months. At 12 months, a patient treated with Stellarex cost
w450V less than PTA (3575V vs. 4027V); at 24 months the difference increased to
w800V (3611V vs 4409V). Extrapolated to 25,000 PAD patients, the use of
Stellarex has the potential to save the healthcare system over 11,000,000V at 12
months and nearly 20,000,000V at 24 months. The number of patients treated with
Stellarex (compared to PTA) to prevent one TLR was 4 at 12 months and 3 at 24
months.
Conclusions: An initial treatment strategy using the Stellarex DCB was associated
with reduced long term TLR between 12 and 24 months vs. PTA. This has the po-
tential to result in a signiﬁcant reduction in healthcare expenditures through two years
post-treatment. Prospective, comparative outcomes data are needed to validate this
model.
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Background: We explored the incidence and pattern of repeat peripheral vascular
intervention (PVI) procedures in patients with peripheral arterial disease (PAD).
Methods:We studied patients undergoing percutaneous PVI in 2012 and 2013 among
47 Hospitals in Michigan that participate in the BMC2 - VIC registry. To identify
return visits, we applied a matching algorithm that used Date of Birth, Gender, Zip
code, and Race.
Results: Of 18381 total PVI procedures, 3263 (17%) patients had multiple PVIs and
these patients accounted for 7720 (42%) of all PVIs in the cohort. Of the multiple PVI
patients, 235 (7.4%) had a PVI on the same vessel as the index PVI, 551 (17.4%) had
PVI on both the same and an additional vessel, and 2377 (75.2%) had PVI on a
different vascular bed. 94% of the PVIs performed in the entire cohort were on lower
extremity (LE).The most frequently used devices for initial LE PVI were balloon (B),1/Suppl B j September 13–17, 2014 j TCT Abstracts/Iliac and SFA
